The Top 5 Biosimilar Articles for the Week of April 4

Here are the top 5 biosimilar articles for the week of April 4, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 4, 2022.

Number 5: White bagging is wreaking havoc for patients and creates liability issues for hospital pharmacies, according to experts who appeared on a panel during the National Comprehensive Cancer Network (NCCN) annual meeting, which was held in a virtual format.

Number 4: During the month of March, rheumatology biosimilars have received a lot of praise in a regulatory, business, and legal sense, especially regarding the landmark settlement between Alvotech and AbbVie over an adalimumab biosimilar.

Number 3: Julie M. Reed, the executive director of the Biosimilars Forum, called for policies to support adoption of lower-cost biologics.

Number 2: An article reviewed the totality of evidence leading to the approval of Amgen’s infliximab biosimilar ABP 710 (Avsola), which is currently approved in the US and Canada for all the indications of the originator (Remicade).

Number 1: A series of initiatives to improve uptake of the biosimilars for 7 originator biologics resulted in significant savings for Providence St. Joseph Health.

To read all of these articles and more, visit centerforbiosimilars.com.